As CLINSCIENCE, we proudly support Professors' Jacek Kubica and Eliano Navarese research team in the regulatory processes for a unique research project assessing the impact of two widely available cardiovascular drugs on the course of SARS-CoV-2 infection.
ReCOVery-SIRIO study is a non-commercial COVID-19 clinical trial designed by researchers from Nicolaus Copernicus University in Poland. Currently, this trial is being evaluated by the Ethics Committee and is expected to start in Poland on May 15, 2020. Polish Competent Authority received the application of April 27, 2020, and issued a positive decision on May 8, 2020.
Clinical evidence indicates that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with confirmed COVID-19 infection (https://clinicaltrials.gov/ct2/show/NCT04351763).